251 related articles for article (PubMed ID: 26351814)
1. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
Grothey A
Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
[No Abstract] [Full Text] [Related]
2. Regorafenib in metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
[No Abstract] [Full Text] [Related]
3. Regorafenib in the treatment of metastatic colorectal cancer.
de la Fouchardière C
Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
[TBL] [Abstract][Full Text] [Related]
4. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
5. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
Draper A
Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
[No Abstract] [Full Text] [Related]
7. Metastatic colorectal cancer.
Prescrire Int; 2017 Feb; 26(179):51. PubMed ID: 30726636
[No Abstract] [Full Text] [Related]
8. Regorafenib: start low and go slow.
Tabchi S; Ghosn M
Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
[No Abstract] [Full Text] [Related]
9. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.
Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A
Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027
[TBL] [Abstract][Full Text] [Related]
10. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
Mitchell J; Khoukaz T; McNeal D; Brent L
Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
[No Abstract] [Full Text] [Related]
12. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Goldberg R
Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
[No Abstract] [Full Text] [Related]
13. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.
Tsuchihashi K; Shimokawa H; Takayoshi K; Nio K; Aikawa T; Matsushita Y; Wada I; Arita S; Ariyama H; Kusaba H; Sonoda KH; Akashi K; Baba E
Medicine (Baltimore); 2017 Oct; 96(42):e8285. PubMed ID: 29049226
[TBL] [Abstract][Full Text] [Related]
15. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
[TBL] [Abstract][Full Text] [Related]
16. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
[No Abstract] [Full Text] [Related]
17. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
[No Abstract] [Full Text] [Related]
18. Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.
Pimenta JR; Racy DJ; Zapata LM; D'Alpino Peixoto R
J Gastrointest Cancer; 2021 Jun; 52(2):784-787. PubMed ID: 32944848
[No Abstract] [Full Text] [Related]
19. Regorafenib in metastatic colorectal cancer.
Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
Kyrochristos ID; Ziogas DE; Roukos DH
Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
